World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
113
Citations
65502
World Ranking
4848
National Ranking
2629

Overview

Lisa A. Carey is affiliated with the University of North Carolina at Chapel Hill in the United States. Their research spans significant areas of medicine, particularly focusing on oncology and related fields. The scientist has contributed extensively to topics such as breast cancer therapies, HER2/EGFR in cancer research, cancer treatment and pharmacology, and cancer genomics and diagnostics.

The researcher's main fields of study include Medicine, with a substantial output in Biochemistry, Genetics, and Molecular Biology. Subfields of study where they have made notable contributions include Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Radiology, Nuclear Medicine and Imaging, and Molecular Biology.

Lisa A. Carey's work covers several key research topics, including:

  • Advanced Breast Cancer Therapies
  • HER2/EGFR in Cancer Research
  • Breast Cancer Treatment Studies
  • Cancer Treatment and Pharmacology
  • Cancer Genomics and Diagnostics
  • Cancer Immunotherapy and Biomarkers
  • Estrogen and related hormone effects

Their publication record features papers in prominent venues such as UNC Libraries, Journal of Clinical Oncology, Cancer Research, Annals of Oncology, and Clinical Cancer Research. The number of publications in these venues reflects a focus on clinical oncology and cancer research.

Recent publications authored or co-authored by Lisa A. Carey include:

  • "Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer," 2021, New England Journal of Medicine
  • "Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update," 2020, Journal of Clinical Oncology
  • "Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline," 2021, Journal of Clinical Oncology
  • "Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021," 2021, Annals of Oncology
  • "Triple negative breast cancer: Pitfalls and progress," 2022, npj Breast Cancer

Frequent co-authors collaborating with Lisa A. Carey include:

  • Charles M. Perou
  • Eric P. Winer
  • Ann H. Partridge
  • Sara M. Tolaney
  • Hope S. Rugo

Best Publications

  • Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.

    Lisa A. Carey;Charles M. Perou;Chad A. Livasy;Lynn G. Dressler

  • The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes

    Lisa A. Carey;E. Claire Dees;Lynda Sawyer;Lisa Gatti

  • The molecular portraits of breast tumors are conserved across microarray platforms

    Zhiyuan Hu;Cheng Fan;Daniel S Oh;JS Marron

  • 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

    F. Cardoso;A. Costa;E. Senkus;M. Aapro

  • Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

    Aditya Bardia;Sara A Hurvitz;Sara M Tolaney;Delphine Loirat

  • Molecular Classification and Molecular Forecasting of Breast Cancer: Ready for Clinical Application?

    James D. Brenton;Lisa A. Carey;Ahmed Ashour Ahmed;Carlos Caldas

  • Epidemiology of basal-like breast cancer

    Robert C. Millikan;Beth Newman;Chiu Kit Tse;Patricia G. Moorman

  • De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017

    G. Curigliano;H. J. Burstein;E. P. Winer;M. Gnant

  • Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)

    William M. Sikov;Donald A. Berry;Charles M. Perou;Baljit Singh

  • Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.

    Rashmi K Murthy;Sherene Loi;Alicia Okines;Elisavet Paplomata

  • Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update.

    Kimberly H. Allison;M. Elizabeth H. Hammond;Mitchell Dowsett;Shannon E. McKernin

  • Triple-negative breast cancer: disease entity or title of convenience?

    Lisa Carey;Eric Winer;Giuseppe Viale;David Cameron

  • Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.

    Sara M. Tolaney;William T. Barry;Chau T. Dang;Denise A. Yardley

  • Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer

    Ayca Gucalp;Ayca Gucalp;Sara Tolaney;Steven J. Isakoff;James N. Ingle

  • Biology, Metastatic Patterns, and Treatment of Patients with Triple-Negative Breast Cancer

    Carey Kernodle Anders;Lisa A Carey

  • Prevalence of articles with honorary authors and ghost authors in peer-reviewed medical journals.

    Annette Flanagin;Lisa A. Carey;Phil B. Fontanarosa;Stephanie G. Phillips

  • Molecular Characterization of Basal-Like and Non-Basal-Like Triple-Negative Breast Cancer

    Aleix Prat;Barbara Adamo;Maggie C.U. Cheang;Carey K. Anders

  • Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline

    Larissa A. Korde;Mark R. Somerfield;Lisa A. Carey;Jennie R. Crews

  • TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer

    Lisa A. Carey;Hope S. Rugo;P. Kelly Marcom;Erica L. Mayer

  • Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021.

    H J Burstein;G Curigliano;B Thürlimann;W P Weber

Frequent Co-Authors

Charles M. Perou
Charles M. Perou University of North Carolina at Chapel Hill
Eric P. Winer
Eric P. Winer Yale University
Hope S. Rugo
Hope S. Rugo University of California, San Francisco
Clifford A. Hudis
Clifford A. Hudis Memorial Sloan Kettering Cancer Center
Joel S. Parker
Joel S. Parker University of North Carolina at Chapel Hill
Ann H. Partridge
Ann H. Partridge Harvard University
Ian E. Krop
Ian E. Krop Harvard University
Antonio C. Wolff
Antonio C. Wolff Johns Hopkins University
Sara M. Tolaney
Sara M. Tolaney Harvard University
Aleix Prat
Aleix Prat University of Barcelona

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

While studying Medicine in the USA typically requires on-campus clinical work, there are alternative online pathways for those interested in the healthcare field. For individuals looking to develop leadership and management skills in healthcare without direct patient care, pursuing cahme accredited online healthcare administration programs can be a strong choice. These programs offer flexible, reputable options to build expertise in healthcare management.

Nurses seeking career advancement may consider an rn to bsn online without clinicals program, allowing registered nurses to earn a bachelor’s degree while balancing work and family obligations. For even higher credentials, online doctoral nursing programs are growing in popularity. There are several dnp online programs that accelerate completion for experienced nurses.

Those searching for more accessible doctoral options should explore easiest online dnp programs, which can reduce barriers to doctoral education in nursing. Whether your goal is administration, leadership, or advanced clinical practice, these online degrees expand your opportunities and can complement a medical education.

Best Scientists Citing Lisa A. Carey

Trending Scientists